Threshold dumps two-thirds of its staff after a crushing failure

Damian Garde

Pharmaceuticals, whose Merck KGaA-partnered oncology therapy failed in a pair of trials this month, is laying off the majority of its workers and rallying around a midstage cancer drug.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS